Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
- 24 May 2006
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 59 (1) , 17-21
- https://doi.org/10.1007/s00280-006-0253-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal AdenocarcinomaJournal of Clinical Oncology, 2005
- Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)Journal of Clinical Oncology, 2005
- Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II TrialJapanese Journal of Clinical Oncology, 2002
- Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinomaAnnals of Oncology, 2000
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnnals of Oncology, 1997
- Chemotherapy of gastric cancerAnti-Cancer Drugs, 1996
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials GroupBritish Journal of Cancer, 1994
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993
- Chemotherapy of gastric cancerCancer Treatment Reviews, 1988